NERV

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

Wall Street analysts forecast NERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NERV is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Minerva Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Minerva Neurosciences Inc. EPS for the last quarter amounts to -0.36 USD, decreased -112.12 % YoY.

Minerva Neurosciences Inc (NERV) has 8 emplpoyees as of December 15 2025.

Today NERV has the market capitalization of 27.13M USD.